Nieuws

Fire disrupts production at GSK Pharma's contract manufacturing site
GSK Pharmaceuticals reports a temporary production disruption due to a fire at one of its contract manufacturing facilities; ...
Investing.com3d
GSK neemt fase III-medicijn efimosfermin over voor $ 1,2 mld.
Het Britse farmaceutische bedrijf GSK (NYSE:GSK) heeft woensdag aangekondigd dat het efimosfermin, een potentieel specialistisch geneesmiddel dat momenteel in fase III van klinische studies verkeert, ...
CNBCTV1818u
Fire at GSK Pharma’s contract manufacturing unit disrupts operations
The company is working closely with the contract manufacturing facility for resumption of operations. Shares of ...
Investing.com2d
GSK neemt nieuwe behandeling voor leverziekte over
GSK plc (LSE/NYSE: GSK) heeft de overname aangekondigd van efimosfermin alfa, een veelbelovende behandeling voor steatotische leverziekte (SLD), van Boston Pharmaceuticals. De deal, met een directe ...
GSK buys liver disease drug for up to $2 bn
British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...
BioPharma Dive2d
GSK to buy liver disease drug for $1.2B
With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...
GSK advances Friday, outperforms market
GSK PLC GSK shares rose 2.35% to £13.95 Friday, on what proved to be an all-around positive trading session for the stock ...
Medical Dialogues1d
GSK to acquire liver disease drug Efimosfermin for up to USD 2 billion
London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...
The Pharma Letter1d
GSK to acquire rights to liver disease drug efimosfermin
Aiming to expand its hepatology portfolio, UK pharma major GSK (LSE: GSK) yesterday announced that it has entered into an ...
GlobalData on MSN2d
GSK to spend $2bn on Phase III liver disease drug acquisition
Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...
PMLive1d
GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn
GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...
Fierce Pharma1d
GSK sponsors Lifetime movie for meningitis B vaccine awareness, with help from 'Buffy' stars
A kidnapped child, a husband with a double life, a treacherous murder plot unraveled when the police arrive at the perfect ...